ADVFN US – Market Content Editor
-
uniQure shares jump 36% after news of FDA gene therapy chief’s departure
Shares of uniQure BV (NASDAQ:QURE) surged 36% on Monday after reports emerged that the head of the U.S. Food and Drug Administration’s vaccines and gene therapies division will step down, triggering several analyst upgrades across the biotechnology sector. Other companies in the space also rallied, with REGENXBIO (NASDAQ:RGNX) rising 13% and Biohaven (NYSE:BHVN) gaining 23%.…
-
Oracle refutes reports of issues at Abilene AI data center
Oracle Corporation (NYSE:ORCL) rejected recent media claims suggesting problems at its major AI data center in Abilene, Texas, saying the project remains on schedule and that it has secured the full 4.5 gigawatts of capacity pledged to OpenAI. Despite the clarification, Oracle shares were down 1.2% at $152.96 in pre-market trading, reflecting broader weakness across…
-
FuelCell Energy shares drop nearly 5% after Q1 loss despite strong revenue growth
FuelCell Energy, Inc. (NASDAQ:FCEL) reported fiscal first-quarter 2026 results on Monday, posting revenue of $30.5 million alongside an adjusted loss per share of $0.52 as the company continues shifting its strategy toward supplying power solutions for data centers. Shares of the company fell 4.74% in pre-market trading following the announcement. Revenue increased 61% year over…
-
Applied Optoelectronics stock rises on $200M transceiver order
Applied Optoelectronics Inc. (NASDAQ:AAOI) shares rose 2% Monday after the company announced it received its first volume order for 1.6T data center transceivers from a major hyperscale customer. The initial order totals more than $200 million and is expected to return the customer to its previous status as a 10%+ customer for Applied Optoelectronics, according to…
-
Boundless Bio posts smaller-than-expected Q4 loss
Boundless Bio (NASDAQ:BOLD) reported a fourth-quarter loss of $0.58 per share, beating analyst expectations for a loss of $1.16 per share, as the clinical-stage oncology company began enrolling patients in the first-in-human study of its BBI-940 therapy. The stock showed little movement in after-hours trading following the release of the results. Net loss for the…
-
Precision BioSciences shares jump after FDA grants Fast Track status to Duchenne therapy
Shares of Precision BioSciences (NASDAQ:DTIL) rose 13% on Monday after the U.S. Food and Drug Administration granted Fast Track designation to PBGENE-DMD, the company’s gene-editing therapy for Duchenne muscular dystrophy. The Fast Track designation is intended to accelerate the development and regulatory review of treatments for serious conditions. It also enables more frequent interactions with…
-
Korro shares jump 17% following $85M private placement financing
Korro Bio Inc. (NASDAQ:KRRO) shares climbed 17% on Monday after the company announced an oversubscribed $85 million private investment in public equity (PIPE) financing. The financing round was led by new investor Venrock Healthcare Capital Partners and included participation from both new and existing investors such as ADAR1 Capital Management, Affinity Asset Advisors, Balyasny Asset…
-
Eltek shares gain nearly 4% after revenue tops expectations despite quarterly loss
Eltek Ltd. (NASDAQ:ELTK) reported fourth-quarter results on Monday that showed a loss of $0.05 per share while generating revenue of $13.24 million, representing a 23% increase from $10.8 million recorded in the same quarter a year earlier. The company said the year was affected by operational changes tied to the integration of new plating lines,…
-
Five key themes for markets in the week ahead
The conflict involving Iran continues to intensify at the start of the new week, pushing oil prices above $100 per barrel and fueling concerns about renewed global inflation pressures. At the same time, the Federal Reserve has entered its policy blackout period as a series of important inflation and labor market data releases approach. On…
-
Pfizer shares slip despite encouraging trial results for eczema treatment
Pfizer Inc (NYSE:PFE) shares declined 1.15% to $26.74 in premarket trading Monday, even after the pharmaceutical company reported positive mid-stage clinical trial results for its experimental antibody therapy targeting atopic dermatitis. The drugmaker said the antibody, tilrekimig, showed meaningful improvement in symptoms of the chronic inflammatory skin condition during the study. According to Pfizer, a…